Genalyte has introduced Maverick ENA 4 and ENA 6 assay kits, designed for use on the company’s Maverick detection system to simultaneously screen several autoantibodies found in autoimmune connective tissue disorders, including systemic lupus erythematosus (SLE).
The Maverick ENA 4 assay tests for the presence of four commonly measured extractable nuclear antigens (ENA), including SS-A, SS-B, Sm and RNP, while the Maverick ENA 6 assay tests for two additional commonly measured antigens, namely Scl-70 and Jo-1.
By using very small volume samples from a variety of matrices including serum and plasma, the assays’ one-step workflow delivers results in 15 minutes.
The assays, which are available to participants in Genalyte’s early access programme, enable scientists to gain pre-launch access to multiplexed autoantibody assays and the Maverick detection system.
Dr. Cary Gunn, Genalyte CEO, said the capabilities of the company’s silicon photonics-based Maverick multiplexing detection system is well suited for autoimmune testing.
"Our first Maverick assays enable researchers to simultaneously assess the most common antibodies associated with SLE and other autoimmune connective tissue diseases," Gunn added.
"We also are developing a number of higher plexed assays for autoimmune diseases, including rheumatoid arthritis, celiac disease and others.
"The Maverick early access programme generated considerable interest at recent immunology meetings, and we look forward to working with our early access collaborators as they put the Maverick detection system to work in their labs."
The Maverick ENA 4 and ENA 6 assays are currently available for research use only, according to the company.